As Takeda Pharmaceutical’s patent on Actos gets closer to its August expiration, the company is making efforts to offset the decreased profits it will lose to generic versions of the drug.
The company expects to miss out on over $2 billion in revenue to generic versions of its flagship drug.
Takeda has been preparing for this potential shift for a good length of time. The Japanese pharmaceutical giant has spent nearly $15 billion on overseas acquisitions over the past two years. The company’s acquisition of URL Pharma will allow access to profits made by the drug Colcrys, which is used to treat and prevent gout.
Actos has been strongly linked to bladder cancer. Many people who have been diagnosed with bladder cancer after taking Actos have joined mass tort lawsuits against Takeda. If you have suffered from the deadly adverse side effects of Actos, contact the Actos lawsuit counsel of Williams Kherkher at 800-641-9810.